Skip to main content

Archana Shanker and Devinder Singh Rawat discuss the rise and regulation of biosimilar biologics in the Indian pharmaceutical market.

Biologics are an important component of the pharmaceutical industry and have grown exponentially in the last decade. In recent years, the pharmaceutical industry has tended to developing biopharmaceutical-based drugs. Most successful biologics are on the verge of patent expiry or have already expired. Furthermore, biotechnological medicine has shown huge potential in curing the unmet demand of small drug molecules. These factors have caught the attention of the global pharmaceutical industry, and have polarised the pharmaceutical industry towards biologic products. Biosimilar biologics are expected to become the most important economic and therapeutic drivers of the pharmaceutical market in India.

This article was published in IP Focus Life Sciences 2013.

To continue reading, please contact us at email@anandandanand.com

Most Recent

News & Insights

VIEW ALL
News & Updates
Aug 25, 2025

At the FICCI–ICRIER Conference on SEPs (23rd August 2025), our Managing Partner Mr. Pravin Anand shared his vision on how India can evolve from being

Conference on Standard Essential Patents (SEPs)
News & Updates
Aug 24, 2025

‘Intellectual Property for a company/ creator is as critical and important as human rights for an individual,’ this guiding belief at ANAND AND ANAND

IAM Strategy 300
Thought Leadership
Aug 21, 2025

‘First published on IAM’ By:  Vaishali R Mittal Patent examination by the Indian Patent Office (IPO) has slowed down dramatically over the last few

Patent examination slowdown risks harming India’s IP momentum
Thought Leadership
Jul 28, 2025

‘First published on Asia IP’ By: Pravin Anand In the book What is Life, written in 1944 by theoretical physicist Erwin Schrödinger, the author states: “A

Human versus machine consciousness